Glenmark Pharmaceuticals has attached a media release today titled ‘Glenmark Specialty S.A. receives approval for conducting Phase 1 Clinical Trial of its Novel Molecule GRC 54276 in patients with Advanced Solid Tumors and Hodgkin’s Lymphoma’.
The above information is a part of company’s filings submitted to BSE.